DARA BioSciences Announces Soltamox® Distribution Partnership in the Commonwealth of Puerto Rico

<0> DARA BioSciences Announces Soltamox® Distribution Partnership in the Commonwealth of Puerto Rico </0>

<0> For DARA BioSciences, Inc.Fountain Square Communications LLCJack Domeischel, 516-480-8813 </0>

DARA BioSciences, Inc. (NASDAQ: DARA)

(Nasdaq:DARA) announced today that it has entered into an exclusive distribution agreement with for the sale and distribution of (tamoxifen citrate, oral solution) in the Commonwealth of Puerto Rico. DARA plans to launch Soltamox later this year.

, DARA's chief executive officer, stated: "The exclusive agreement with Seyer Pharmatec to sell and distribute Soltamox in Puerto Rico leverages DARA's existing commercial infrastructure, provides DARA with a well-respected and established commercial partner, and presents an opportunity to make Soltamox and potential future cancer-support products readily available for patients in this important market. Since DARA has exclusive rights to market Soltamox in the United States and its territories and possessions, our partnership with Seyer Pharmatec will help us maximize Soltamox sales.”

Soltamox is the first and only FDA-approved oral liquid formulation of tamoxifen citrate, a first-line therapy for the prevention and treatment of breast cancer. A significant number of breast cancer patients may have difficulty swallowing pills. This leads some patients to crush pills, mix them with food, or miss doses. Due to difficulty swallowing solid tablets, some patients may discontinue therapy altogether. The availability of liquid tamoxifen offers women with breast cancer a convenient, comfortable and easy-to-swallow alternative.

Seyer Pharmatec is focused on acquiring or in-licensing innovative pharmaceutical products, such as Soltamox, for the Puerto Rico market. With a seasoned national sales force and fully integrated distribution services, Seyer is recognized as a leading specialty pharmaceutical company in Puerto Rico.

DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA sharpened its focus in oncology through its January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox®. Soltamox is a novel oral liquid formulation of tamoxifen citrate, a product used widely in the treatment and prevention of breast cancer. Soltamox is the only FDA approved oral liquid version of tamoxifen citrate and fulfills a vital clinical need for patients who cannot tolerate existing solid tablet formulations of this drug. DARA plans to begin marketing Soltamox in the U.S. later this year. Additionally, in June 2012 DARA launched its first product, Bionect, a topical treatment for skin irritation and burns associated with radiation therapy.

Prior to acquiring Oncogenerix, DARA was focused on the development of a cancer-support therapeutic compound, KRN5500, for the treatment of neuropathic pain in patients with cancer. This product is an excellent fit with DARA’s strategic oncology focus, has successfully completed a Phase IIa study, and has been designated as a Fast Track Drug by the United States Food and Drug Administration. DARA is working with the National Cancer Institute (NCI) to design an additional clinical trial under joint DARA-NCI auspices while considering further Phase 2 development.

In addition to its oncology products, DARA’s pipeline includes DB959, a novel, non-TZD dual delta/gamma, PPAR agonist for the treatment of type 2 diabetes and dyslipidemia. DARA has completed Phase I testing of DB959 and is presently pursuing opportunities to out-license this product.

DARA also has rights to other PPAR and DPPIV-inhibitor compounds for which it intends to seek out-licensing or partnering opportunities.

For more information please visit our web site at .